UT Health small current research text box

Furr Stimming Erin smallPrincipal Investigator: Erin Furr-Stimming, MD

Research Institution: McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth)

Disease: Huntington's Disease

Research Description: Huntington’s disease (HD) is a devastating inherited neurologic disease that encompasses motor, cognitive, and psychiatric symptoms. Common psychiatric symptoms, including depression, irritability, impulsivity, and apathy, may precede the onset of motor symptoms. Irritability in HD may lead to aggressive behavior and emotional outbursts that can be harmful to both the patient and caregiver. The current medications available to treat irritability in individuals with HD are off label and often have unwanted side effects. The research team proposes a clinical trial using Nuedexta, a drug approved in 2010 for pseudobulbar affect, to address irritability in HD. Nuedexta has been studied in patients with Alzheimer's disease and was found to significantly improve agitation. Results from the proposed study have the potential to identify an effective medication to improve patient quality of life by addressing this disruptive and destructive behavioral symptom of HD.

CWR Funding Role: Primary funder

CWR Funding Partner: Anonymous

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please contact our Admin support at admin@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Monday the 16th. Copyright 2018 Cures Within Reach.